• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Market characteristics o COVID-19 impact on healthcare sector o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2020 o Market outlook: Forecast for 2020-2025 • Five Forces Analysis o Five forces summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Indication o Market segments o Comparison by Indication o Rhinitis - Market size and forecast 2020-2025 o Sinusitis - Market size and forecast 2020-2025 o Otitis media - Market size and forecast 2020-2025 o Tonsillitis - Market size and forecast 2020-2025 o Market opportunity by Indication • Customer Landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2020-2025 o Europe - Market size and forecast 2020-2025 o Asia - Market size and forecast 2020-2025 o ROW - Market size and forecast 2020-2025 o Key leading countries o Market opportunity by geography o Market drivers o Market challenges o Market trends • Vendor Landscape o Overview o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o AbbVie Inc. o ALK-Abello AS o Bayer AG o Covis Pharma BV o F. Hoffmann-La Roche Ltd. o GlaxoSmithKline Plc o Johnson & Johnson o Merck & Co. Inc. o Pfizer Inc. o Sanofi SA • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2020 - 2025 ($ million) • 13: Global market: Year-over-year growth 2020 - 2025 (%) • 14: Five forces analysis 2020 & 2025 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2020 • 21: Other1 - Market share 2020-2025 (%) • 22: Comparison by Other1 • 23: Rhinitis - Market size and forecast 2020-2025 ($ million) • 24: Rhinitis - Year-over-year growth 2020-2025 (%) • 25: Sinusitis - Market size and forecast 2020-2025 ($ million) • 26: Sinusitis - Year-over-year growth 2020-2025 (%) • 27: Otitis media - Market size and forecast 2020-2025 ($ million) • 28: Otitis media - Year-over-year growth 2020-2025 (%) • 29: Tonsillitis - Market size and forecast 2020-2025 ($ million) • 30: Tonsillitis - Year-over-year growth 2020-2025 (%) • 31: Market opportunity by Other1 • 32: Customer landscape • 33: Market share by geography 2020-2025 (%) • 34: Geographic comparison • 35: North America - Market size and forecast 2020-2025 ($ million) • 36: North America - Year-over-year growth 2020-2025 (%) • 37: Europe - Market size and forecast 2020-2025 ($ million) • 38: Europe - Year-over-year growth 2020-2025 (%) • 39: Asia - Market size and forecast 2020-2025 ($ million) • 40: Asia - Year-over-year growth 2020-2025 (%) • 41: ROW - Market size and forecast 2020-2025 ($ million) • 42: ROW - Year-over-year growth 2020-2025 (%) • 43: Key leading countries • 44: Market opportunity by geography ($ million) • 45: Market share by geography 2020-2025 (%) • 46: Geographic comparison • 47: Impact of drivers and challenges • 48: Vendor landscape • 49: Landscape disruption • 50: Industry risks • 51: Vendors covered • 52: Market positioning of vendors • 53: AbbVie Inc. - Overview • 54: AbbVie Inc. - Business segments • 55: AbbVie Inc. - Key offerings • 56: AbbVie Inc. - Key customers • 57: AbbVie Inc. - Segment focus • 58: ALK-Abello AS - Overview • 59: ALK-Abello AS - Product and service • 60: ALK-Abello AS - Key offerings • 61: ALK-Abello AS - Key customers • 62: ALK-Abello AS - Segment focus • 63: Bayer AG - Overview • 64: Bayer AG - Business segments • 65: Bayer AG - Key offerings • 66: Bayer AG - Key customers • 67: Bayer AG - Segment focus • 68: Covis Pharma BV - Overview • 69: Covis Pharma BV - Product and service • 70: Covis Pharma BV - Key offerings • 71: Covis Pharma BV - Key customers • 72: Covis Pharma BV - Segment focus • 73: F. Hoffmann-La Roche Ltd. - Overview • 74: F. Hoffmann-La Roche Ltd. - Business segments • 75: F. Hoffmann-La Roche Ltd. - Key offerings • 76: F. Hoffmann-La Roche Ltd. - Key customers • 77: F. Hoffmann-La Roche Ltd. - Segment focus • 78: GlaxoSmithKline Plc - Overview • 79: GlaxoSmithKline Plc - Business segments • 80: GlaxoSmithKline Plc - Key offerings • 81: GlaxoSmithKline Plc - Key customers • 82: GlaxoSmithKline Plc - Segment focus • 83: Johnson & Johnson - Overview • 84: Johnson & Johnson - Business segments • 85: Johnson & Johnson - Key offerings • 86: Johnson & Johnson - Key customers • 87: Johnson & Johnson - Segment focus • 88: Merck & Co. Inc. - Overview • 89: Merck & Co. Inc. - Business segments • 90: Merck & Co. Inc. - Key offerings • 91: Merck & Co. Inc. - Key customers • 92: Merck & Co. Inc. - Segment focus • 93: Pfizer Inc. - Overview • 94: Pfizer Inc. - Business segments • 95: Pfizer Inc. - Key offerings • 96: Pfizer Inc. - Key customers • 97: Pfizer Inc. - Segment focus • 98: Sanofi SA - Overview • 99: Sanofi SA - Business segments • 100: Sanofi SA - Key offerings • 101: Sanofi SA - Key customers • 102: Sanofi SA - Segment focus • 103: Currency conversion rates for US$ • 104: Research Methodology • 105: Validation techniques employed for market sizing • 106: Information sources • 107: List of abbreviations

AbbVie Inc., ALK-Abello AS, Bayer AG, Covis Pharma BV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Sanofi SA